Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy

Cancer Gene Therapy

Volumn 21, Issue 11, 2014, Pages 463-471

  Buijs, P R A ^a   Van Amerongen, G ^b   Van Nieuwkoop, S ^a   Bestebroer, T M ^a   Van Run, P R W A ^a   Kuiken, T ^a   Fouchier, R A M ^a   Van Eijck, C H J ^a   Van Den Hoogen, B G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Viroclinics Biosciences   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; NEWCASTLE DISEASE VACCINE; ONCOLYTIC VIRUS; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; VIRUS VACCINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHICKEN; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG USE; HISTOPATHOLOGY; MACACA FASCICULARIS; MALE; MOLECULAR CLONING; NEWCASTLE DISEASE VIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; RNA VIRUS; SEROCONVERSION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; ZYGOTE; ANIMAL; CELL LINE; CHICK EMBRYO; COMPARATIVE STUDY; DOSE RESPONSE; DRUG SCREENING; FETUS MEMBRANE; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; PROCEDURES; SERODIAGNOSIS; SITE DIRECTED MUTAGENESIS; VIROLOGY; VIRUS SHEDDING;

ANIMALIA; AVES; MACACA FASCICULARIS; NEWCASTLE DISEASE VIRUS; PARAMYXOVIRIDAE; PRIMATES;

ALLANTOIS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CHICK EMBRYO; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; MALE; MUTAGENESIS, SITE-DIRECTED; NEUTRALIZATION TESTS; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRAL VACCINES; VIRUS SHEDDING;

EID: 84927176136     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2014.51     Document Type: Article

References (42)

1. Mayo MA. A summary of taxonomic changes recently approved by ICTV. Arch Virol 2002; 147: 1655-1663.
2. Kraneveld FC. Over een in Ned.-Indië heerschende ziekte onder het pluimvee. Nederlands-Indische bladen voor Diergeneeskunde 1926; 38: 448-450.
3. Council of the European Communities. Council Directive 92/66/EEC of 14 July 1992 introducing Community measures for the control of Newcastle disease. In. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31992L0066:EN:NOT, 1992.
4. Collins MS, Bashiruddin JB, Alexander DJ. Deduced amino acid sequences at the fusion protein cleavage site of Newcastle disease viruses showing variation in antigenicity and pathogenicity. Arch Virol 1993; 128: 363-370.
5. Dortmans JC, Koch G, Rottier PJ, Peeters BP. Virulence of newcastle disease virus: what is known so far? Vet Res 2011; 42: 122.
6. Peeters BP, de Leeuw OS, Koch G, Gielkens AL. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 1999; 73: 5001-5009.
7. OIE: World Organisation for Animal Health Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. In. http://www.oie.int/fileadmin/Home/eng/Health-standards/tahm/2.03.14-NEWCASTLE-DIS.pdf, 2012.
8. Shimkin NI. Conjunctival haemorrhage due to an infection of Newcastle virus of fowls in man; laboratory and contact infection. Br J Ophthalmol 1946; 30: 260-264.
9. Keeney AH, Hunter MC. Human infection with the Newcastle virus of fowls. AMA Arch Ophthalmol 1950; 44: 573-580.
10. Nelson CB, Pomeroy BS, Schrall K, Park WE, Lindeman RJ. An outbreak of conjunctivitis due to Newcastle disease virus (NDV) occurring in poultry workers. Am J Public Health Nations Health 1952; 42: 672-678.
11. Quinn RW, Hanson RP, Brown JW, Brandly CA. Newcastle disease virus in man; results of studies in five cases. J Lab Clin Med 1952; 40: 736-743.
12. Evans AS. Pathogenicity and immunology of Newcastle disease virus (NVD) in man. Am J Public Health Nations Health 1955; 45: 742-745.
13. Trott DG, Pilsworth R. Outbreaks of conjunctivitis due to the Newcastle disease virus among workers in chicken-broiler factories. Br Med J 1965; 2: 1514-1517.
14. Hales RH, Ostler HB. Newcastle disease conjunctivitis with subepithelial infiltrates. The Br J Ophthalmol 1973; 57: 694-697.
15. Bell J. Oncolytic viruses: an approved product on the horizon? Mol Ther 2010; 18: 233-234.
16. Zamarin D, Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol 2012; 7: 347-367.
17. Csatary LK, Bakacs T. Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA 1999; 281: 1588-1589.
18. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002; 20: 2251-2266.
19. Csatary LK, Gosztonyi G, Szeberenyi J, Fabian Z, Liszka V, Bodey B et al. MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol 2004; 67: 83-93.
20. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006; 13: 221-228.
21. Laurie SA, Bell JC, Atkins HL, Roach J, Bamat MK, O'Neil JD et al. A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res 2006; 12: 2555-2562.
22. Wagner S, Csatary CM, Gosztonyi G, Koch HC, Hartmann C, Peters O et al. Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid. APMIS 2006; 114: 731-743.
23. Hotte SJ, Lorence RM, Hirte HW, Polawski SR, Bamat MK, O'Neil JD et al. An optimized clinical regimen for the oncolytic virus PV701. Clin Cancer Res 2007; 13: 977-985.
24. Lorence RM, Roberts MS, O'Neil JD, Groene WS, Miller JA, Mueller SN et al. Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets 2007; 7: 157-167.
25. Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res 2007; 67: 8285-8292.
26. Altomonte J, Marozin S, Schmid RM, Ebert O. Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther 2010; 18: 275-284.
27. Kumar R, Tiwari AK, Chaturvedi U, Kumar GR, Sahoo AP, Rajmani RS et al. Velogenic Newcastle disease virus as an oncolytic virotherapeutics: in vitro characterization. Appl Biochem Biotechnol 2012; 167: 2005-2022.
28. Biswas M, Johnson JB, Kumar SR, Parks GD, Elankumarana S. Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion. J Virol 2012; 86: 12708-12716.
29. Herfst S, de Graaf M, Schickli JH, Tang RS, Kaur J, Yang CF et al. Recovery of human metapneumovirus genetic lineages a and B from cloned cDNA. J Virol 2004; 78: 8264-8270.
30. Buijs PR, van Eijck CH, Hofland LJ, Fouchier RA, van den Hoogen BG. Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection. Cancer Gene Ther 2014; 21: 24-30.
31. Hirst GK. The quantitative determination of influenza virus and antibodies by means of red cell agglutination. J Exp Med 1942; 75: 49-64.
32. Munster VJ, Baas C, Lexmond P, Bestebroer TM, Guldemeester J, Beyer WE et al. Practical considerations for high-throughput influenza A virus surveillance studies of wild birds by use of molecular diagnostic tests. J Clin Microbiol 2009; 47: 666-673.
33. Xie L, Xu F, Liu S, Ji Y, Zhou Q, Wu Q et al. Age-and sex-based hematological and biochemical parameters for Macaca fascicularis. PLoS One 2013; 8: e64892.
34. Wise MG, Suarez DL, Seal BS, Pedersen JC, Senne DA, King DJ et al. Development of a real-time reverse-transcription PCR for detection of newcastle disease virus RNA in clinical samples. J Clin Microbiol 2004; 42: 329-338.
35. Rimmelzwaan GF, Baars M, van Beek R, de Lijster P, de Jong JC, Claas EC et al. Influenza virus subtype cross-reactivities of haemagglutination inhibiting and virus neutralising serum antibodies induced by infection or vaccination with an ISCOM-based vaccine. Vaccine 1999; 17: 2512-2516.
36. Bukreyev A, Huang Z, Yang L, Elankumaran S St, Claire M, Murphy BR et al. Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol 2005; 79: 13275-13284.
37. DiNapoli JM, Kotelkin A, Yang L, Elankumaran S, Murphy BR, Samal SK et al. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci USA 2007; 104: 9788-9793.
38. DiNapoli JM, Yang L, Suguitan A Jr., Elankumaran S, Dorward DW, Murphy BR et al. Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. J Virol 2007; 81: 11560-11568.
39. DiNapoli JM, Ward JM, Cheng L, Yang L, Elankumaran S, Murphy BR et al. Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans. Vaccine 2009; 27: 1530-1539.
40. DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A. Respiratory tract immunization of non-human primates with a Newcastle disease virusvectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 2010; 29: 17-25.
41. DiNapoli JM, Nayak B, Yang L, Finneyfrock BW, Cook A, Andersen H et al. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol 2010; 84: 1489-1503.
42. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966; 50: 219-244.